Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 2, 1998, Pages 265-271

  Weiss, S M ^a   Wadsworth, G ^a   Fletcher, A ^a   Dourish, C T ^a  

^a Cerebrus Limited   (United Kingdom)

Author keywords

Animal model; Anxiety; D amphetamine; Elevated plus maze; Elevated zero maze; Locomotor activity; Risk assessment; Stretched attend posture; Validity

Indexed keywords

ANXIOLYTIC AGENT; CHLORDIAZEPOXIDE; DEXAMPHETAMINE; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ETHOLOGY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; REARING; RISK ASSESSMENT;

EID: 0032421076     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(98)00027-X     Document Type: Conference Paper

References (30)

1. Baldwin H. A., Johnston A. L., File S. E. Antagonistic effect of caffeine and yohimbine in animal tests of anxiety. Eur. J. Pharmacol. 159:1989;211-215.
2. Balfour D. J. K., Graham C. A., Vale A. L. Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural response to nicotine and diazepam in an elevated plus-maze. Psychopharmacology. 103:1986;229-232.
3. Blanchard DC, Blanchard RJ, Rodgers RJ. Risk assessment in animal models of anxiety. In: Olivier B, Mos J, Slangen JL, editors. Animal models in psychopharmacology. Basel: Birkhauser, 1991. pp. 117-134.
4. Cruz A. P. M., Frei F., Graeff F. G. Ethopharmacological analysis of rat behaviour on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
5. Dawson G. R., Crawford S. P., Collinson N., Iversen S. D., Tricklebank M. D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus-maze are confounded by increases in locomotor activity. Psychopharmacology. 118:1995;316-323.
6. Dawson G. R., Tricklebank M. D. Use of an elevated plus-maze in the search for novel anxiolytics agents. Trends Pharmacol. Sci. 16:1995;33-36.
7. Derrien M., McCort-Tranchepain I., Ducos B., Roques B. P., Durieux C. Heterogeneity of CCK-B receptor involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
8. File SE. The biological basis of anxiety. In: Meltzer HY, Nerozzi D, editors. Current practices and future developments in the pharmacotherapy of mental disorders. Amsterdam: Elsevier, 1991. pp. 159-165.
9. File S. E., Aranko K. Sodium valproate and chlordiazepoxide in the elevated plus-maze test of anxiety in the rat. Neuropsychobiology. 20:1988;82-86.
10. Fowler H. Curiosity and exploratory behaviour. New York: MacMillian, New York, 1966.
11. Gray JA. The neuropsychology of anxiety. An enquiry into the functions of the septo-hippocampal system. Oxford: Clarendon Press, 1982.
12. 2C receptors but not by symphathomimetic effects. Neuropharmacology. 33:1994;457-465.
13. Griebel G., Moreau J.-L., Jenck F., Martin J. R., Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav. Process. 30:1993;37-48.
14. Handley S. L., McBlane J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Tox. Meth. 30:1993;130-138.
15. Handley S. L., Mithani S. Effects of α-adrenoceptor agonists and antagonists in a maze-exploration model of "fear" motivated behaviour. Naunyn-Schmeidebergs Arch. Pharmacol. 329:1984;1-5.
16. Klint T. Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats. Behav. Pharmacol. 2:1991;481-489.
17. Lister R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
18. Lister RG. Ethologically based animal models of anxiety disorders. In: File SE, editor. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon Press, 1991. pp. 155-185.
19. Matthew R. J., Wilson W. H. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology. 21:1989;117-123.
20. Montgomery K. C. The relation between fear induced by novel stimulation and exploratory behaviour. J. Compr. Physiol. Psychol. 48:1955;264-280.
21. Moser P. C. An evaluation of the elevated plus-maze using the novel anxiolytic buspirone. Psychopharmacology. 99:1989;48-53.
22. Paulus M. P., Geyer M. A. A temporal scaling hypothesis for the behavioural effects of psychostimulants. Psychopharmacology. 104:1991;6-16.
23. Pellow S., Chopin P., File S. E., Briley M. Validation of open:closed arm entries into an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
24. Pellow S., File S. E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;526-530.
25. Reynolds JEF. Martindale. The extra pharmacopeia, vol. 29. London: The Pharmaceutical Press, 1989. pp. 1440-1441.
26. Rodgerio R., Takahashi R. N. Anxiogenic action of acute but not repeated cocaine administration in handling-habituated mice in the plus-maze test. Brazilian J. Med. Biol. Res. 26:1992;713-716.
27. Rodgers R. J., Cao B.-J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Brazilian J. Med. Biol. Res. 30:1997;299-304.
28. Rodgers RJ, Cole JC. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA, editors. Ethology and psychopharmacology. Chichester: Wiley, 1994, pp. 9-44.
29. Rodgers R. J., Shepherd J. K. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regime and prior maze experience. Psychopharmacology. 106:1992;102-110.
30. Shepherd J. K., Grewal S. S., Fletcher A., Bill D. J., Dourish C. T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology. 116:1994;56-64.